ABCDx, a Swiss Spanish MedTech company developing blood-based point-of-care diagnostic solutions for acute care, has been awarded funding through the Spanish Red.IA Salud program for the development of EmboCheck, its next-generation solution for pulmonary embolism.
The project represents an overall programme of approximately €3 million, with around €1.4 million in non-dilutive funding allocated to ABCDx.
EmboCheck is being developed as a rapid point-of-care solution combining blood biomarkers, clinical information and AI-based risk stratification to support the assessment of patients with suspected pulmonary embolism, particularly in emergency and pre-hospital settings.
The programme will support the further development ofthe biomarker panel, software and AI components, as well as clinical validationand regulatory activities aimed at progressing EmboCheck toward future CEmarking.
“This grant is an important milestone for ABCDx. It gives us the resources to accelerate EmboCheck while further developing the common technology platform behind our acute-care diagnostic products,” said Jean-Charles Sanchez, CEO and Co-founder of ABCDx. “Pulmonary embolism remains a major diagnostic challenge, especially when rapid access to laboratory testing or imaging is limited. Our objective is to bring clinically useful information closer to the patient and earlier in the care pathway.”
The Red.IA Salud award builds on ABCDx’s existing clinical and regulatory programmes for LVOCheck, its blood-based solution for the identification of large-vessel occlusion stroke.
Together, these programmes reinforce ABCDx’s strategy of developing a multi-indication point-of-care diagnostic platform combining biomarkers, lateral-flow technologies, smartphone-based image analysis and clinical algorithms across acute neurological and cardiovascular conditions.
About ABCDx
ABCDx is a Swiss Spanish MedTech company developing blood-based point-of-care diagnostic solutions for acute and emergency care. Its technology combines biomarkers, lateral-flow assays, smartphone-based image analysis and clinical algorithms to support faster and more objective clinical decision-making.
The company’s lead programmes include LVOCheck, for large-vessel occlusion stroke, and EmboCheck, for pulmonary embolism.
ABCDx operates in Switzerland and Spain, with activities spanning biomarker discovery, clinical research, software, AI, regulatory development and point-of-care diagnostics.
MediaContact
Tamara Sefcovicova
PR, Marketing andOffice Operations Specialist
